Business Description
Haemonetics Corp
NAICS : 325413
SIC : 3845
ISIN : US4050241003
Share Class Description:
STU:HAZ: Ordinary SharesTotal Employee Number:
3,009Description
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.2 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.54 | |||||
Debt-to-EBITDA | 4.56 | |||||
Interest Coverage | 8.38 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.49 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.4 | |||||
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 51.3 | |||||
3-Year Book Growth Rate | 2.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.26 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.13 | |||||
9-Day RSI | 57.04 | |||||
14-Day RSI | 60.14 | |||||
3-1 Month Momentum % | 19.34 | |||||
6-1 Month Momentum % | -13.43 | |||||
12-1 Month Momentum % | -7.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.95 | |||||
Quick Ratio | 1.87 | |||||
Cash Ratio | 0.87 | |||||
Days Inventory | 225.69 | |||||
Days Sales Outstanding | 55.98 | |||||
Days Payable | 36.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.6 | |||||
Shareholder Yield % | 5.13 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.04 | |||||
Operating Margin % | 18.03 | |||||
Net Margin % | 7.29 | |||||
EBITDA Margin % | 20.12 | |||||
FCF Margin % | 19.45 | |||||
OCF Margin % | 21.91 | |||||
ROE % | 11.42 | |||||
ROA % | 3.97 | |||||
ROIC % | 8.96 | |||||
3-Year ROIIC % | 11.08 | |||||
ROC (Joel Greenblatt) % | 24.27 | |||||
ROCE % | 8.03 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.13 | |||||
Forward PE Ratio | 14.66 | |||||
PE Ratio without NRI | 15.09 | |||||
Shiller PE Ratio | 43.7 | |||||
Price-to-Owner-Earnings | 28.11 | |||||
PEG Ratio | 1.09 | |||||
PS Ratio | 2.66 | |||||
PB Ratio | 4.26 | |||||
Price-to-Free-Cash-Flow | 13.6 | |||||
Price-to-Operating-Cash-Flow | 12.07 | |||||
EV-to-EBIT | 27.99 | |||||
EV-to-Forward-EBIT | 16.37 | |||||
EV-to-EBITDA | 16.34 | |||||
EV-to-Revenue | 3.29 | |||||
EV-to-Forward-Revenue | 3.15 | |||||
EV-to-FCF | 16.85 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Projected-FCF | 1.37 | |||||
Price-to-Median-PS-Value | 0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.77 | |||||
Earnings Yield (Greenblatt) % | 3.57 | |||||
FCF Yield % | 7.64 | |||||
Forward Rate of Return (Yacktman) % | 23.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Haemonetics Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,146.593 | ||
| EPS (TTM) (€) | 1.727 | ||
| Beta | 0.8788 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 76.82 | ||
| 14-Day RSI | 60.14 | ||
| 14-Day ATR (€) | 2.398563 | ||
| 20-Day SMA (€) | 64.55 | ||
| 12-1 Month Momentum % | -7.2 | ||
| 52-Week Range (€) | 40.2 - 73.5 | ||
| Shares Outstanding (Mil) | 45.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Haemonetics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Haemonetics Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-06 08:00 | In 129 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 06:00 | In 129 days | ||
| First quarter earnings conference call for 2027 | 2026-08-07 08:00 | In 38 days | ||
| First quarter earnings results for 2027 | 2026-08-07 06:00 | In 38 days | ||
| General meeting for 2026 | 2026-07-24 08:00 | In 24 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 16:00 | 61.50 (+4.24%) | ||
| Annual report for 2026 | 2026-05-20 | 48.80 (+3.83%) | ||
| Guidance call for 2026 | 2026-05-12 08:00 | 44.20 (-3.07%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-07 08:00 | 44.80 (-3.45%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-07 06:00 | 44.80 (-3.45%) |
Show
Entries
Haemonetics Corp Frequently Asked Questions
What is Haemonetics Corp(STU:HAZ)'s stock price today?
The current price of STU:HAZ is €65.50. The 52 week high of STU:HAZ is €73.50 and 52 week low is €40.20.
When is next earnings date of Haemonetics Corp(STU:HAZ)?
The next earnings date of Haemonetics Corp(STU:HAZ) is 2026-08-07 Est..
Does Haemonetics Corp(STU:HAZ) pay dividends? If so, how much?
Haemonetics Corp(STU:HAZ) does not pay dividend.
Press Release
Articles on Haemonetics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers